Selling, General, and Administrative Costs: Novartis AG vs Summit Therapeutics Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing costs is as crucial as innovation. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Novartis AG and Summit Therapeutics Inc., from 2014 to 2023.

Novartis AG: A Steady Giant

Novartis AG, a global leader, consistently reported SG&A expenses in the range of $12.5 billion to $16.5 billion annually. Despite a slight decline of approximately 17% from 2018 to 2023, Novartis maintains a robust financial strategy, reflecting its scale and market presence.

Summit Therapeutics Inc.: A Rising Contender

In contrast, Summit Therapeutics Inc. shows a dynamic growth trajectory. Starting with expenses of around $6.8 million in 2014, they surged by over 300% to $28.2 million by 2023. This growth underscores Summit's expanding operations and strategic investments.

This comparison highlights the diverse financial strategies within the pharmaceutical sector, offering insights into how companies navigate their growth and operational challenges.